Experimental study of huxintongluo decoction on rabbit atherosclerosis by intervening CETP mediated lipid metabolism

doi:10.11958/20212849

Abstract

Abstract:

Objective To study the effect and mechanism of huxintongluo decoction on rabbit atherosclerosis (AS) by regulating cholesterol lipid transporter protein (CETP). Methods Forty male New Zealand rabbits were divided into the blank control group, the AS model group, the simvastatin group [0.33 mg/(kg·d)] and the huxintongluo group [0.34 g/(kg·d)] according to random number table method, with 10 rabbits in each group. The blank control group was fed ordinary diet for 22 weeks. The other three groups were fed with high fat diet for 14 weeks, and then different drug intervention was performed in groups for 8 weeks. Serum levels of high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), total cholesterol (TC) and triglyceride (TG) were detected before the experiment, 14 and 22 weeks after administration. The animals were sacrificed at the end of the 22-week, the thoracic aorta was separated, and the pathological changes were observed by hematoxyl-eosin (HE) staining. The expression levels of ABCA1, apoA-I and LCAT in liver tissues were detected by fluorescence quantitative PCR and Western blot assay. Results There were no significant differences in serum levels of TC, TG, HDL-C and LDL-C before the experiment between the four groups (P>0.05). At week 14 of experiment, compared with the blank control group, serum levels of TC, TG and HDL-C were significantly increased in the other three groups, while the serum level of LDL-C was significantly decreased (P<0.05). At week 22 of experiment, compared with the AS model group, serum levels of TC, TG and LDL-C were significantly decreased in the other three groups, while serum level of HDL-C was significantly increased (P<0.05). Compared with the blank control group, the serum level of CETP increased in the AS model group. Compared with the AS model group, the serum level of CETP decreased in the simvastatin group and the huxintongluo group. Compared with the blank control group, ABCA1, apoA-I and LCAT mRNA and protein levels in liver tissues were decreased in the AS model group. Compared with the AS model group, mRNA and protein levels of ABCA1, apoA-I and LCAT were increased in the simvastatin group and the Huxintongluo group (P<0.05). Conclusion Huxintongluo decoction can activate ABCA1/apoA-I/LCAT pathway by reducing CETP level, ultimately improve HDL-C level and improve atherosclerosis in rabbits.

Key words: atherosclerosis, cholesterol, HDL, rabbits, huxintongluo decoction, cholesterol lipid transporter, ABCA1/apoA-I/LCAT pathways

CLC Number:

Figures/Tables 5

References 17

[1]	KOBIYAMA K, LEY K. Atherosclerosis[J]. Circ Res, 2018, 123(10):1118-1120. doi: 10.1161/CIRCRESAHA.118.313816.
[2]	中华中医药学会心血管病分会. 冠心病稳定型心绞痛中医诊疗专家共识[J]. 中医杂志, 2018, 59(5):447-450.
	Cardiovascular Diseases Branch of China Association of Traditional Chinese Medicine. Expert consensus on TCM diagnosis and treatment of stable angina pectoris of coronary heart disease[J]. Journal of Traditional Chinese Medicine, 2018, 59(5):447-450. doi: 10.13288/j.11-2166/r.2018.05.020.
[3]	ZHANG J, NIIMI M, YANG D, et al. Deficiency of cholesteryl ester transfer protein protects against atherosclerosis in rabbits[J]. Arterioscler Thromb Vasc Biol, 2017, 37(6):1068-1075. doi: 10.1161/ATVBAHA.117.309114.
[4]	徐则林. 护心通络方对高脂血症患者的疗效及对胆固醇逆转运蛋白ABCA1/apoA-I/LCAT的影响[J]. 糖尿病天地, 2020, 17(9):38-39.
	XU Z L. Effect of Huxintongluo Prescription on hyperlipidemia patients and effect on cholesterol-reversing transporters ABCA1/ApoA-I/LCAT[J]. Diabetes World, 2020, 17(9):38-39.
[5]	蔡嘉洛, 曾律滔, 张志国, 等. 护心通络方对高脂血症大鼠内皮细胞凋亡及Bax、Bcl-2蛋白表达的影响[J]. 中医药导报, 2017, 23(24):16-18,23.
	CAI J L, ZENG L T, ZHANG Z G, et al. Effects of Huxin Tongluo Recipe(护心通络方) on apoptosis of endothelial cells and expression of Bax and Bcl-2 proteins in hyperlipidemic rats[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacology, 2017, 23(24):16-18,23.
[6]	丁宗君. 他汀类药物治疗慢性肝病的临床应用及不良反应研究进展[J]. 中国药物滥用防治杂志, 2022, 28(3):273-277.
	DING Z J. Clinical application and adverse reactions of statins in the treatment of chronic liver disease[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2022, 28(3):273-277. doi: 10.15900/j.cnki.zylf1995.2022.03.001.
[7]	ĆWIKLIŃSKA A, STRZELECKI A, KORTAS-STEMPAK B, et al. ApoE-containing HDL and the development of atherosclerosis[J]. Postepy Hig Med Dosw(Online), 2015, 69:1-9. doi: 10.5604/17322693.1134724.
[8]	XEPAPADAKI E, ZVINTZOU E, KALOGEROPOULOU C, et al. The antioxidant function of HDL in atherosclerosis[J]. Angiology, 2020, 71(2):112-121. doi: 10.1177/0003319719854609.
[9]	OSSOLI A, PAVANELLO C, GIORGIO E, et al. Dysfunctional HDL as a therapeutic target for atherosclerosis prevention[J]. Curr Med Chem, 2019, 26(9):1610-1630. doi: 10.2174/0929867325666180316115726.
[10]	冯冬萍, 屠强, 杨梦溪, 等. 胆固醇酯转运蛋白抑制剂对动脉粥样硬化性心血管疾病影响的研究进展[J]. 中国动脉硬化杂志, 2019, 27(7):629-634.
	FENG D P, TU Q, YANG M X, et al. Current status of cholesteryl ester transfer protein inhibitors in atherosclerotic cardiovascular disease[J]. Chinese Journal of Arteriosclerosis, 2019, 27(7):629-634. doi: 10.3969/j.issn.1007-3949.2019.07.015.
[11]	ZHU J, WEI S, HUANG L, et al. Molecular modeling and rational design of hydrocarbon-stapled/halogenated helical peptides targeting CETP self-binding site:Therapeutic implication for atherosclerosis[J]. J Mol Graph Model, 2020, 94:107455. doi: 10.1016/j.jmgm.2019.107455.
[12]	WESNIGK J, BRUYNDONCKX L, HOYMANS V Y, et al. Impact of lifestyle intervention on HDL-induced eNOS activation and cholesterol efflux capacity in obese adolescent[J]. Cardiol Res Pract, 2016, 2016:2820432. doi: 10.1155/2016/2820432.
[13]	OUIMET M, BARRETT T J, FISHER E A. HDL and reverse cholesterol transport[J]. Circ Res, 2019, 124(10):1505-1518. doi: 10.1161/CIRCRESAHA.119.312617.
[14]	CIMMINO G, GIANNARELLI C, CHEN W, et al. Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO mice:comparison of intramuscular and intravenous administration[J]. J Cardiovasc Pharmacol, 2011, 57(3):325-333. doi: 10.1097/FJC.0b013e31820 92841.
[15]	MILLWOOD I Y, BENNETT D A, HOLMES M V, et al. Association of CETP gene variants with risk for vascular and nonvascular diseases among Chinese adults[J]. JAMA Cardiol, 2018, 3(1):34-43. doi: 10.1001/jamacardio.2017.4177.
[16]	ABAJ F, RAFIEE M, KOOHDANI F. Interaction between CETP polymorphism and dietary insulin index and load in relation to cardiovascular risk factors in diabetic adults[J]. Sci Rep, 2021, 11(1):15906. doi: 10.1038/s41598-021-95359-y.
[17]	刘祎, 刘寅, 高静. 胆固醇酯转运蛋白水平与冠心病患者血脂指标的相关性[J]. 天津医药, 2013, 41(6):572-575.
	LIU Y, LIU Y, GAO J. A study on correlation between cholesteryl ester transfer protein and coronary heart disease[J]. Tianjin Med J, 2013, 41(6):572-575. doi: 10.3969/j.issn.0253-9896.2013.06.017.

组别	n	ABCA1	apoA-I	LCAT
空白对照组	10	1.00±0.10	1.00±0.08	1.00±0.13
AS模型组	8	0.59±0.09^a	0.67±0.16^a	0.54±0.17^a
辛伐他汀组	9	0.74±0.08^ab	0.87±0.14^ab	0.76±0.12^ab
护心通络方组	9	0.76±0.05^ab	0.84±0.16^ab	0.73±0.13^ab
F		64.817^＊＊	9.627^＊＊	17.164^＊＊

组别	n	ABCA1	apoA-I	LCAT
空白对照组	10	1.00±0.10	1.00±0.08	1.00±0.13
AS模型组	8	0.59±0.09^a	0.67±0.16^a	0.54±0.17^a
辛伐他汀组	9	0.74±0.08^ab	0.87±0.14^ab	0.76±0.12^ab
护心通络方组	9	0.76±0.05^ab	0.84±0.16^ab	0.73±0.13^ab
F		64.817^＊＊	9.627^＊＊	17.164^＊＊

组别	n	ABCA1	apoA-I	LCAT
空白对照组	10	0.67±0.13	0.71±0.23	0.80±0.11
AS模型组	8	0.34±0.12^a	0.39±0.15^a	0.63±0.12^a
辛伐他汀组	9	0.72±0.08^ab	0.65±0.07^ab	0.81±0.14^b
护心通络方组	9	0.70±0.06^ab	0.66±0.08^ab	0.82±0.17^b
F		25.689^＊＊	7.729^＊＊	3.642^＊

组别	n	ABCA1	apoA-I	LCAT
空白对照组	10	0.67±0.13	0.71±0.23	0.80±0.11
AS模型组	8	0.34±0.12^a	0.39±0.15^a	0.63±0.12^a
辛伐他汀组	9	0.72±0.08^ab	0.65±0.07^ab	0.81±0.14^b
护心通络方组	9	0.70±0.06^ab	0.66±0.08^ab	0.82±0.17^b
F		25.689^＊＊	7.729^＊＊	3.642^＊